Medicine Celltrion unveils promising dose escalation results for subcutaneous infliximab admin October 15, 2024 1 min read Study reveals potential new strategy for managing inflammatory bowel disease Continue Reading Previous: Transgene’s cancer vaccine trial shows mixed resultsNext: Alleo and Ubiquigent unite to accelerate drug discovery Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Related Stories Bluejay begins phase 3 trial of brelovitug for hepatitis D 2 min read Medicine Bluejay begins phase 3 trial of brelovitug for hepatitis D September 10, 2025 Quotient Sciences and CPI launch RNA drug development venture 2 min read Medicine Quotient Sciences and CPI launch RNA drug development venture September 9, 2025 Eisai unveils promising phase 1b data for narcolepsy drug E2086 1 min read Medicine Eisai unveils promising phase 1b data for narcolepsy drug E2086 September 9, 2025
